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Metformin is, if not contraindicated and if tolerated, usually preferred over other antidiabetic drugs for the first line
treatment of type-2 diabetes. The particular decision on which antidiabetic agent to use is based on variables such
as efficacy, cost, potential side effects, effects on weight, comorbidities, hypoglycemia, risk, and patient preferences.
However, there is no guidance how to consider these in the selection of antidiabetic drug treatment. In this work,
we aimed to summarize available evidence and tried to give pragmatic treatment recommendations from a clinical
practice perspective.
There are clear contraindications for some drugs in those with impaired renal and liver function and precautions in
those with heart failure for the use of metformin (NYHA III-IV) and glitazones. On the other hand, GLP-1 analogs,
DPP-4 inhibitors and acarbose are generally less critical and can be used in the majority of patients. We identified
the following gaps with respect to the selection of antidiabetic drug treatment in patients with co-morbid disease
conditions: 1) Guidelines fail to give advice on the use of specific antidiabetic drugs in patients with co-morbidity.
2) The literature is deficient in studies documenting antidiabetic drug use in patients with severely impaired renal
function, diabetic retinopathy, cerebrovascular disease and systolic heart failure. 3) Further there are no specific data
on patients with multiple of these co-morbid disease conditions. We postulate that differential use of antidiabetic
drugs in patients with co-morbid disease constellations will help to reduce treatment related complications and
might improve prognosis.Introduction
There is appropriate guidance for the pharmacotherapy of
patients with type-2 diabetes. In general metformin is, if
not contraindicated and if tolerated, considered the first
line antidiabetic agent [1]. If non-insulin monotherapy
fails in achieving HbA1c targets over 3–6 months, a sec-
ond oral agent or insulin is to be added. The particular de-
cision on which antidiabetic agent to use is however based
on variables such as efficacy, cost, potential side effects, ef-
fects on weight, comorbidities, hypoglycemia, risk, and pa-
tient preferences.
A recent position statement of the American Diabetes
Association (ADA) and the European Association for the
Study of Diabetes (EASD) on a patient-centred approach
in the management of patients with type-2 diabetes [2]
gives an overview on how different glucose-lowering* Correspondence: diethelm.tschoepe@ruhr-uni-bochum.de
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reproduction in any medium, provided the oragents may impact treatment choices when co-morbid
disease conditions are considered. Even at acceptable
levels of glucose control, these comorbidities have a sub-
stantial impact on well-being as measured by the SF-36
and EQ-5D [3,4]. Because these considerations are im-
portant but difficult to translate into clinical practice,
we aimed to summarize available evidence and tried to
phrase expert opinion from a clinical practice perspec-
tive. We refrained, in general, to comment upon non-
antidiabetic drugs as they are beyond the scope of the
current review.
This overview was consolidated over the course of a
total of two board meetings in which the authors
discussed the data on antidiabetic pharmacotherapy in
patients with co-morbid disease conditions. On this
basis a tabular overview for pragmatic decision making
from a clinical practice perspective was developed
(Figure 1).l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Insulin Acarbose Glitazones SU Glinides Glycaemic 
control
Obesity
(BMI > 30 kg/m2)
yes yes yes O yes O O O yes
Albuminuria
(>20 mg/g creatinine)
O O O O O O O O yes
Impaired renal function
(GFR < 60 ml/min)
no (O) 2 (O) 2 yes (O) 2 yes (O) 2 yes yes
Diabetic retinopathy
(Proven by fundoscopy)
O O O O O O O O yes
Cardiovascular disease
(CAD, AMI, PCI, CABG)
(yes) 3 (yes) 4 (yes) 4 (yes) 3 yes (yes) 4 O O O
Cerebrovascular disease
(Stroke)
(yes) 5 (yes) 4 (yes) 4 (yes) 3 yes (yes) 4 O O O
Systolic heart failure
(EF <50%; NYHA ≥ II)
(yes) 6 (no) 7 (yes) 4 (yes) 4 (O) 3 yes no O O O
Liver dysfunction (yes) 8 (no) 9 O O O O O no no O
Severe hypoglycaemia1
(> 1/yr with 3rd party assistance)
yes (yes) 4 (yes) 4 O yes yes O O O
Hospitalized patients O10 O O yes O O O10 O O
Elderly
(> 65 years)
yes (yes) 4 (yes) 4 (yes) 3 O O O O O
1 requiring third party assistance; 2 contraindicated Acarbose < 25 ml/min, DPP-4 < 50 ml/min, Exenatide < 30 ml/min, Liraglutide < 60 ml/min, SU < 30 ml/min; 3 only in 
those without hypoglycaemia; 4 no clear consensus because of a lack of data; 5 Metformin contraindicated within 2 weeks after stroke; 6 Metformin recommended in those 
with NYHA class I-II heart failure; 7 contraindicated in those with NYHA class III-IV heart failure; 8 Metformin recommended in hepatopathy without liver failure; 9
Metformin is contraindicated for patients with advanced liver failure; 10 Metformin and SU should be stopped if fasting periods or radiological contrast studies are envisioned
Figure 1 Co-morbidity adjusted selection of antidiabetic drugs based on expert opinion.
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In 2010 the prevalence of obesity among adult patients with
type 2 diabetes in US was 56.9%, according to the Centres
for Disease Control and Prevention. This is not only im-
portant on a quantitative basis but also because obesity in
patients with diabetes is associated with poor control of
blood glucose, making obese patients with diabetes a high
risk population for micro- and macrovascular events.
It appears that metformin is the principal choice for
obese patients with type-2 diabetes because it is neutral
with respect to weight. This has been shown in the United
Kingdom Prospective Diabetes Study (UKPDS) in which
even weight loss was observed for metformin users [5]. On
the other hand, the Body Mass Index (BMI) itself appears
to have no effect on the reduction of HbA1c or glycaemic
control with metformin either alone or in combination with
other drugs [5-9], although there are selected data to show
that obese patients receiving metformin appear to have a
greater chance to achieve target levels of HbA1c < 7% with-
out additional antidiabetic drugs than patients receiving
sulfonylurea (SU) or insulin [10]. Dipeptidyl peptidase-
4 (DPP-4) inhibitors and bile acid sequestrants are
weight-neutral [11,12]. Liraglutide and exenatide havecomparable effects on weight, but liraglutide may have a
greater effect than exenatide on glycemic control, when
used as a second-line therapy [13]. The newer available
agents, glucagon-like peptide-1 (GLP-1) agonists promote
weight loss. In recent meta-analyses, GLP-1 analogs, were
associated with weight loss when added to metformin [11]
or to a combination therapy of metformin and SU [14].
Insulin and insulin analogues seem to induce weight
gain as a recent meta-analysis showed that insulin and
glitazones were associated to weight gain when added to
a combination therapy of metformin and SU [14]. A 6-
year follow-up of the UKPDS also showed that weight
gain was more pronounced in insulin- than in SU- (and
metformin-) treated patients [5]. On the other hand,
glitazones, SU, and glinides are also associated to weight
gain when added to metformin [11]. Despite their effect
on weight gain, HbA1c reduction and glycemic control
with sitagliptin, nateglinide, glyburide, SU or insulin do
not seem to be affected by BMI [5-9].
Expert opinion
Metformin appears to be the primary choice for obese pa-
tients with type-2 diabetes (Figure 1). For metformin-treated
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cose of 70 to 130 mg/dl or post-prandial glucose below 180
mg/dl, second-line treatment choices in order of weight
benefit would be: GLP-1 agonists, DPP-4 inhibitors,
acarbose, bile acid sequestrants, and amylin analogs. If insu-
lin treatment is indicated, a basal insulin supplementation
should be considered.
Antidiabetic therapy in patients with albuminuria
Diabetic nephropathy is characterized by albuminuria
and abnormal glomerular function and is a major cause
of renal failure. The prevalence of microalbuminuria
(MAU) among those with type-2 diabetes was 39% in
the Developing Education on Microalbuminuria for
Awareness of Renal and Cardiovascular Risk in Diabetes
(DEMAND) survey [15].
In patients with MAU it has been shown that an intensi-
fied glucose lowering treatment is superior to standard of
care in reducing levels of MAU [16]. However, data on re-
duction of albuminuria with particular antidiabetic drugs are
scarce: Sitagliptin was shown to reduce MAU in a small
pilot study in 36 patients with type-2 diabetes [17]. This was
most likely depending on risk factor control such as, among
other undetermined factors, blood glucose, blood pressure
and inflammation reduction. For glitazones (rosiglitazone),
there is a subanalysis of the A Diabetes Outcomes Prevention
Trial (ADOPT) trial, in which 4,351 recently diagnosed,
drug-naïve patients with type-2 diabetes were treated and
followed for up to 5 years with rosiglitazone, metformin, or
glyburide [18]. While the albumin/creatinine ratio (ACR)
rose slowly with metformin it fell with rosiglitazone (and less
so with glyburide) within the first 2 years, but slowly in-
creased during the following years. Blood pressure with
rosiglitazone was reduced compared to the other treatment
options. The data contradict a previous study, however,
which compared rosiglitazone versus glyburide for the re-
duction of urinary albumin excretion, where no significant
difference in the reduction of baseline albuminuria between
the two drugs was observed [19].
The most relevant study related to MAU is probably the
Steno-2 study, which showed that intensive therapy -
consisting on tight glucose regulation, lifestyle modifica-
tion, and the use of the renin-angiotensin system blockers,
aspirin, and lipid-lowering agents- had sustained beneficial
effects with respect to vascular complications, renal dis-
ease, and on total and cardiovascular death in type 2 dia-
betes patients with persistent MAU [20].
Expert opinion
No firm recommendations can be derived based on the
available literature (Figure 1). The only justified recom-
mendation seems to be a multifactorial intensive inter-
vention to control glucose more tight than in those
without albuminuria.Antidiabetic therapy in patients with impaired
renal function
Diabetes is the leading cause of kidney failure, account-
ing for 44% of all new cases of kidney failure in 2008 in
the United States [21]. The clearance of antidiabetic
drugs is decreased and results in prolonged exposure to
higher levels of the drug or its metabolites that may trigger
adverse events. Observational data suggest that mortality
risk in patients with type 2 diabetes and renal dysfunction
increases with HbA1c levels < 6.5% and > 8.0%. Accord-
ingly, HbA1c levels between 6.5% and 7.5% may be a rea-
sonable target for these patients [22].
A number of antidiabetic drugs are contraindicated in
patients when glomerular filtration rate (GFR) falls
below variable thresholds, such as 25 ml/min for
acarbose, 30 ml/min for exenatide and SU, 50 ml/min
for DPP-4 inhibitors and 60 ml/min for metformin and
liraglutide. There are scant data on the actual efficacy
and safety of diabetes medications depending on pa-
tients’ renal function. Furthermore, contraindications do
not necessarily match with available evidence. This is ex-
emplified with metformin [23]: The label of metformin in
the U.S. allows the prescription of metformin at or above
1.4 mg/dl serum creatinine in women and 1.5 mg/dl
in men. In Germany, metformin is contraindicated in
patients with a GFR < 60 ml/min. In the U.K. prescribing
guidelines consider both creatinine and GFR for assessing
treatment eligibility. The National Institute for Health and
Clinical Excellence (NICE) recommends reviewing pre-
scriptions when serum creatinine exceeds 1.5 mg/dl or
GFR falls below 45 ml/min per 1.73 m2 and to stop
treatment at a serum creatinine of 1.7 mg/dl or a GFR
of below 30 ml/min per 1.73 m2. The uncertainty is
mirrored in clinical practice when metformin is pre-
scribed despite full knowledge of the relevant cut-offs.
Nevertheless, there is no evidence from prospective
comparative or observational studies that metformin
confers an increased risk of lactic acidosis. This was
shown in a meta-analysis from 347 comparative trials
and cohort studies [24].
Insulin is generally considered to be safe in patients with
a reduced kidney function. When there is a reduction of
renal function, its half-life is prolonged because of lower
levels of degradation [25]. This has been shown to increase
the frequency of hypoglycaemic events which may be five
times as frequent as in patients without kidney disease [26].
Available pharmacokinetic and clinical studies suggest
that DPP-4 inhibitors may be safe in patients with renal
impairment. Because of their variable degree of renal
clearance (except for linagliptin), they may however need
dose adjustment. Additionally, DPP-4 inhibitors have a
decreased risk of hypoglycemia [27].
As outlined above, glitazones may have a protective ef-
fect to either prevent or slow the progression of diabetic
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ferred over other drugs for the treatment of patients
with diabetes. It further undergoes hepatic metabolism
and has been demonstrated to be effective without an
increased risk of hypoglycemia in patients with chronic
kidney disease [28]. However, fluid retention may be ac-
centuated and appropriate measures should be taken.
Expert opinion
Impairment of renal function is an important co-
morbidity to be considered when selecting antidiabetic
drugs (Figure 1). When taking a GFR < 60 ml/min metfor-
min is contraindicated as is liraglutide. Other thresholds
apply to DPP-4 inhibitors (<50), exenatide and SU (<30)
and acarbose (<25 ml/min). Generally recommended are
glitazones, glinides, insulin, and more recently DPP-4 in-
hibitors, although the dose may have to be adjusted.
Antidiabetic therapy in patients with diabetic
retinopathy
Diabetic retinopathy is the most frequent vascular compli-
cation and the most feared by patients. The prevalence
ranges in newly diagnosed patients ranges from 0 to 30%
[29]. Diabetic macular edema (DME) was present in 4.1%
of type-2 diabetic patients not requiring insulin and 9.1%
in those with insulin in the longitudinal Exeter Diabetic
Retinopathy Screening Program in the UK [30,31].
Optimal glycaemic control is crucial for preventing the
progression of retinopathy. Furthermore, an early achieve-
ment of good glycaemic control in the course of diabetes
has been shown to delay progression of diabetic retinop-
athy independent of glucose control [32]. The use of ret-
inal laser photocoagulation together with intravitreal
therapy with steroids, and more recently, with biologicals
has enabled a second line therapy for DME [33].
Among the antidiabetic drugs insulin has been shown to
directly influence retinal blood flow, vascular tone and
angiogenesis [34]. For glitazones, the UKPDS demon-
strated for each 1% reduction in HbA1c level a corre-
sponding 31% reduced risk of onset or progression of
diabetic retinopathy over 9 years of follow-up [32]. Never-
theless, TZDs have been reported to increase the risk of
DME in a prospective cohort study [35], but data from a
subgroup of the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) eye substudy did not demonstrate a
conclusive link between TZD use and DME [36].
Expert opinion
No conclusive recommendations can be derived based
on the available literature (Figure 1). All agents are
about as good for patients with diabetic retinopathy.
Since the Steno-2 study showed that intensive therapy
significantly reduced the risk of retinopathy by about
60% in type-2 diabetes patients with MAU [20], it seemsjustified an intensive therapy to control glucose more
tight than in those without retinopathy.
Antidiabetic therapy in patients with
cardiovascular disease
Coronary artery disease (CAD) is the most common
cause of morbidity and mortality in patients with type-2
diabetes. In 2004, heart disease was noted on 68% of
diabetes-related death certificates among people aged 65
years or older in the United States [21].
It has been postulated that metformin might promote
CAD [37] and is known to bear the additional risk of
lactic acidosis, especially in patients with recent myocar-
dial infarction [38]. Fisman et al. even found an increase
of mortality in CAD patients receiving metformin after a
5-year follow-up [39]. These findings should, however,
be considered with caution, since the study was non-
randomized. A direct comparison of metformin with
other antidiabetic drugs is only available from two retro-
spective cohort studies. The first included 8,494 patients
after myocardial infarction in Denmark and found lower
mortality rates for metformin than for SU users and risk
appeared to be increased in men [40]. The second in-
cluded patients with a prior diagnosis of ischemic heart
disease treated with metformin and documented a lower
all-cause mortality for metformin than for either SU or
repaglinide [41]. Nevertheless, a recently published meta-
analysis could not demonstrate the benefit/risk ratio of
metformin [42]. Therefore, further studies are warranted
to clarify the effects of metformin on cardiovascular mor-
tality and morbidity among patients with type 2 diabetes.
A meta-analysis of 35 trials including 8,478 patients
examined the effect of insulin on mortality in the hyper-
glycemic critically ill patient, mostly after myocardial in-
farction [43]. It demonstrated that insulin decreased
short-term mortality by 15%. A considerable benefit was
noted in patients with type-2 diabetes mellitus (RR 0.73;
95%CI 0.58-0.90) [44]. In the Diabetes Mellitus Insulin
Glucose Infusion in Acute Myocardial Infarction 2
(DIGAMI 2) trial glucose-insulin infusion failed to result
in a survival benefit however [45].
Acarbose is the most extensively studied alpha-
glucosidase inhibitor. In STOP-NIDDM subjects with
prediabetes and early diabetes were included and sug-
gested that acarbose was associated with a 49% risk re-
duction in cardiovascular events [46].
SU, on the other hand, have been reported to reduce
myocardial blood flow, increase infarct size, and to in-
crease early mortality after direct angioplasty for acute
myocardial infarction. These untoward effects have been
reported more so for the first-generation SU such as tol-
butamide [47] than for second-generation compounds.
However, the aforementioned Danish registry found no
difference with respect to the type of SU as to 30-day
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data on the Danish registry on SU suggests that there is
not a class effect on mortality and cardiovascular risk
[49]. The study showed that monotherapy with the most
used SU, including glimepiride, glibenclamide, glipizide,
and tolbutamide, seemed to be associated with increased
mortality and cardiovascular risk compared with metfor-
min. Similar to SU, glinides modify ATP-dependent po-
tassium channels and therefore should be used with
caution.
Expert opinion
In patients with cardiovascular disease, SU or glinides
should rather be avoided and other treatment options
preferred instead (Figure 1). Because of the risk of
hypoglycemia blood glucose targets to be met are sug-
gested to be less tight compared to patients without car-
diovascular disease.
Antidiabetic therapy in patients with
cerebrovascular disease
In 2004, stroke was noted on 16% of diabetes-related
death certificates among people aged 65 years or older
in the United States and the risk for stroke is 2 to 4
times higher among people with diabetes [21]. When
considering antidiabetic treatment in stroke patients
three different situations have to be considered. 1)
Preadmission use of antidiabetic drugs; 2) antidiabetic
drug use after acute stroke and 3) antidiabetic drug use
in patients with anamnestic stroke.
1) In a Danish follow-up study of 4,817 patients
hospitalized with ischemic stroke between 2003 and
2006 [50] the preadmission use of metformin,
insulin, and patients without antidiabetic
pharmacotherapy had a lower 30-day mortality
compared with users of SU. However, no significant
differences were observed in 1-year mortality rates.
TZDs were shown to reduce infarct volume and
improve neurologic function following transient
middle cerebral artery occlusion in rats [51].
2) Antidiabetic drugs during acute stroke are based on
the association of hyperglycemia with poor outcome
after acute ischemic stroke. The 2007 American
Heart / American Stroke Association guidelines
suggest treating at lower glucose levels based on
expert opinion [52]. One of the few studies
investigating pharmacotherapy in this situation was
the Glycemia in Acute Stroke study (GLIAS), a
multicenter, prospective, and observational cohort
study of 476 acute ischemic stroke patients [53].
Capillary blood glucose ≥155 mg/dl was associated
with a 4-fold increase in the odds of poor outcome
at 3 months after adjustment for age, gender,hypertension, diabetes, stroke severity, admission
glycemia, and infarct volume. The UK Glucose
Insulin Stroke Trial (GIST-UK) suggests that most
acute stroke patients will only have mild to
moderate increases in plasma glucose at
presentation (median 7.6 mmol/l) with minimal
insulin requirement as a consequence [54].
Metformin is contraindicated in patients within 2
weeks after stroke.
3) We found no data to prefer any antidiabetic drug
over another in patients with anamnestic stroke.
Expert opinion
Recommendations for those with cerebrovascular dis-
ease in general match those with cardiovascular disease
(Figure 1). While SU and glinides should be avoided, all
other treatment options can be used to control blood
glucose as appropriate.
Antidiabetic therapy in patients with (systolic)
heart failure
Patients with type-2 diabetes are at high risk for devel-
oping systolic heart failure. In a population based cohort
(Saskatchewan Health database, Canada) of patients with
recent-onset type-2 diabetes the incidence was 6% over
5.2 years [55]. Pharmacotherapy is particularly difficult
in this patient group as anti-diabetic medication may im-
pair myocardial energy metabolism, thus influencing
symptoms and clinical outcome. Although metformin is
contraindicated in these patients in some countries, a re-
cent systematic review by Eurich revealed that treatment
with metformin may be associated with lower mortality
rates, lower rates of all cause hospital admission, and
less adverse events [56]. Data from the UKPDS showed
that the risk for heart failure was not significantly differ-
ent between the groups treated with metformin and its
controls [57]. Furthermore, a study conducted in
Denmark prospectively followed 10,920 patients hospi-
talized for the first time for heart failure in 1997–2006
and who were receiving metformin, SU and/or insulin.
The study showed that treatment with metformin was
associated with a low risk of mortality in diabetic pa-
tients with heart failure compared with treatment with
SU or insulin [58].
Data available for acarbose in patients with heart failure
are limited. In a meta-analysis of seven randomized, con-
trolled studies with a minimum treatment duration of 52
weeks in type-2 diabetic patients and no heart failure at
baseline incident heart failure was rare (about1%) and
there was a trend towards a reduced incidence of heart
failure with acarbose (HR 0.55 (95%CI 0.21-1.45) [59]. In-
sulin has been found to have positive inotropic effects on
myocardial tissue and improved hemodynamics in pa-
tients with systolic heart failure. A retrospective cohort
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nosis of heart failure found no association between the
use of insulin and mortality in comparison to other
antidiabetic drugs [60].
Expert opinion
It appears that glitazones and, in NYHA III-IV heart fail-
ure, metformin should not be used in patients with heart
failure (Figure 1). Other drugs such as insulin, SU and
glinides are less likely to produce untoward effects. Gener-
ally preferred are drugs such as metformin (NYHA I-II),
acarbose and GLP-1 analogs / DPP-4 inhibitors although
the evidence base for the recommendation of the latter is
weak.
Antidiabetic therapy in patients with liver
dysfunction
Liver dysfunction, particularly non-alcoholic fatty liver
disease (NAFLD), and type 2 diabetes frequently coexist.
Indeed, 49–62% of type 2 diabetes patients have NAFLD
[61]. NAFLD may be a marker of cardiovascular risk and
mortality in type 2 diabetes patients.
Treatment of type 2 diabetes in patients with liver dys-
function is complex as many OADs may be contraindi-
cated because the risk of hypoglycemia may be
magnified, and therefore doses may also need to be ad-
justed. There are only a few reported cases of hepato-
toxic side effects for metformin [62], but there may be
an increased risk of developing lactic acidosis in the set-
ting of impaired liver function. Therefore, metformin is
contraindicated for patients with advanced liver disease.
Nevertheless, the risk of lactic acidosis associated with
metformin seems to accentuate in patients with multiple
comorbidities, particularly when there is an acute deteri-
oration [63]. If a patient has stable liver dysfunction and
few comorbidities, metformin is likely to be reasonably
safe, but the dose should be reduced to 1500 mg daily
maximum and it should be discontinued if renal or liver
function worsens [64-66].
Insulin therapy is probably the safest and most effect-
ive therapy in patients with liver dysfunction, with the
limitation that increased risk of hypoglycemia in such
patients requires extra care with insulin dosage. Regard-
ing SU and glinides, the existence of increased risk of
hypoclycemia due to reduced hepatic gluconeogenesis
should also be considered. Indeed, glinides are contrain-
dicated in the setting of liver dysfunction because they
are mostly cleared through the liver, and SU are contra-
indicated in advanced liver failure.
Data regarding the use of DPP-4 inhibitors in patients
with liver disease are currently lacking.
Patients with moderate liver dysfunction can take
sitagliptin or exenatide [67,68]. Vildagliptin is contrain-
dicated in patients with liver dysfunction as clinicalstudies showed that high doses of this drug increased
hepatic transaminases in some patients [69].
Expert opinion
Type 2 diabetes patients with liver dysfunction are at in-
creased risk of cirrhosis, liver failure and hepatocellular
carcinoma. Identification and tight control of metabolic
risk factors remains the mainstay of treatment. Although
based on the available literature no conclusive recom-
mendations can be derived, given that OADs are contra-
indicated in patients with advanced liver disease, insulin
treatment remains the available option for glycemic
control.
Antidiabetic therapy in patients with episodes of
severe hypoglycaemia
Hypoglycemia is the principal reason that blood glucose
targets are not achieved in many patients and has been
reported to occur at 10 to 70 per 100 patient years [70].
This is associated with an increased rate of cardiovascular
and total mortality [71]. While acarbose, metformin,
pioglitazone, and incretine-based therapies are not associ-
ated with hypoglycemia, a mono- or combination therapy
with insulinotropic OADs such as SU or glinides and in-
sulin have been associated with an increased risk. In the
UKPDS 16% of SU and 36% of insulin treated patients ex-
perienced hypoglycemia [57]. A later study reported sub-
stantially higher rates for glibenclamide (38%) [72] which
would alleviate the difference between SU and insulin
[70]. Furthermore, the risk of hypoglycemia is strongly
dependent on the choice of insulin. Long-acting (analog)
insulins have a lower propensity to induce severe
hypoglycemia compared to neutral protamine Hagedorn
(NPH) insulin. Regarding short acting insulins, a meta-
analysis was conducted to assess its effects compared to
regular human insulin [73]. Their results suggested only a
minor benefit of short acting insulin analogues in terms of
incidence of hypoglycemic events.
Expert opinion
In patients with a history of (severe) hypoglycemia drugs
such as SU, glinides and insulin should be avoided and
less stringent blood glucose targets pursued (Figure 1).
On the other hand, metformin, GLP-1 analogs / DPP-4
inhibitors, acarbose and glitazones appear to confer a
low risk and should be preferred.
Antidiabetic therapy in hospitalized patients
Diabetes is associated with increased hospital admission
and length of hospital stay [74] and there is much evi-
dence that type 2 diabetes increases inpatient morbidity
and mortality [75,76]. Given the particular conditions of
inhospital patients, their treatment requires more flex-
ible strategies to treat hyperglycemia [69].
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recommend that the glucose concentration target value
should be maintained in the 140 to 180 mg/dL range as
long as these values can be achieved safely [77]. Lower tar-
gets can also be considered but it is of utmost importance
to avoid hypoglycemic events. However, one should bear
in mind that the effect of hyperglycemia and mortality rate
among patients with diabetes in surgical, medical and car-
diac intensive care units depends on the admission diag-
nosis, as shown in a study by Falciglia et al. [78].
Insulin is considered the standard of inpatient glucose
management [77]. Nevertheless, if the hospital stay is
expected to be short and metabolic derangements are
unlikely to occur, patients may continue their home regi-
men. After fasting periods, OADs should be only contin-
ued after the first normal meal. Indeed, there are special
recommendations for SU and metformin. Temporarily
discontinuing treatment with SU is recommended if
fasting periods are expected due to increased risk of
hypoglycemia [79]. Metformin should be discontinued
48 hours before the intended procedure and not re-
sumed until the patient tolerates oral food intake and
there are no other contraindications. Insulin can be ad-
ministered when OADs are temporarily discontinued.
Metformin is also contraindicated in contrast studies as
iodinated radiological contrast media may lower the
glomerular filtration rate with the risk of causing renal
failure. Therefore, metformin should be discontinued at
least 24 hours before the contrast study and restarted 48
hours afterward if normal renal function is confirmed.
Similarly, SU should be also temporarily stopped before
radiological tests, as they are mainly cleared through the
kidneys. On the other hand, it should be also considered
that high-dose glucocorticoid treatment increments the
insulin requirement. Specifically, insulin dose should be
adjusted postprandially and 8 to 12 hours after gluco-
corticoid administration [79].Expert opinion
In view of the many restrictions on the use of oral
antidiabetic drugs, temporary insulin treatment remains
the most practical means of glycemic control for many
hospitalized patients with type 2 diabetes. Glucose-
lowering strategies must be chosen individually for each
patient, with consideration of the relevant comorbidities
and special conditions.Antidiabetic therapy in elderly
The majority of patients have to be considered “elderly”
when an age above 65 years is used as a threshold. “The
elderly” however is a heterogeneous group with varying
physiologic profiles, functional capabilities, and life ex-
pectancy. While some are actually “young”, many sufferfrom multiple co-morbidities for which specific consid-
erations have been summarized above [80].
The risk of hypoglycemia is increased in elderly pa-
tients due to impaired renal and hepatic function, drug
interaction and malnutrition [81] and a loss of sensitivity
towards hypoglycemia has been reported [82]. Thus,
HbA1c targets can, correspondingly, be less stringent
[83]. Furthermore, a proper balance of lowering blood
glucose and not getting too low is difficult to accomplish
in the elderly. This is particularly true for SU in which
the risk of hypoglycemia is increased by 36% in the eld-
erly compared with younger adults.
Substantial gastrointestinal side effects may limit the
use of alpha-glucosidase inhibitors particularly in older
patients. There is limited information on the use of
DPP-4 inhibitors in the elderly. DPP-4 inhibitors may,
however need their dose adjusted (see section on ne-
phropathy). There are not sufficient data on exenatide
use in the elderly. It may be beneficial in elderly patients
with reduced mobility who could benefit from weight
loss, whereas it is less optimal for frail, normal weight
adults. However, trials in the elderly have not been
performed in larger cohorts.
A recent study investigated the efficacy and safety of
adding once-daily insulin glargine to patients’ current
OAD treatment and compared this to a strategy of in-
creasing OAD doses in the elderly with poor glycemic
control [84]. During the observation, HbA1c was re-
duced by 1.5% in insulin treated vs. 0.6% in OAD treated
patients. Mean fasting blood glucose decreased by 29
and 15% and insulin treated patients had fewer
hypoglycemic events. The results suggest that the
addition of insulin glargine to oral antidiabetic drugs is
safer with respect to hypoglycemia but as effective in
elderly patients.
Expert opinion
Age is not a co-morbid disease condition per se but usu-
ally a constellation that increases the likelihood of co-
morbid diseases such as those outlined above. Therefore
most of the treatment recommendations for the elderly
have to rely on other co-morbidities (Figure 1). Preferred
drugs in the older patients should, ideally, not be cleared
by the kidney and have a low risk of adverse cardiovas-
cular effects or hypoglycaemia. Generally metformin,
GLP-1 analogs / DPP-4 inhibitors and long-acting insu-
lin should be preferred over other treatment options
(SU, glinides and glitazones).
Perspectives
Randomized, controlled trials often employ narrow in-
clusion criteria, enrolling patients at a low risk for com-
plications, a low degree of co-morbidity and to avoid the
enrollment of patients with adverse effects or poor
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to the selection of antidiabetic drug treatment in pa-
tients with co-morbid disease conditions: 1) Guidelines
fail to advice on the use of specific antidiabetic drugs in
patients with co-morbidity. 2) The literature is deficient
in studies documenting antidiabetic drug use in patients
with severely impaired renal function, diabetic retinop-
athy, cerebrovascular disease and systolic heart failure.
3) Further there are no specific data on patients with
multiple of these co-morbid disease conditions.
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